The Role of Nanobiotechnology in Drug Discovery

  • Kewal K. Jain
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 655)


The potential applications of nanotechnology in life sciences, particularly nanobiotechnology, include those for drug discovery. This chapter shows how several of the nanotechnologies including nanoparticles and various nanodevices such as nanobiosensors and nanobiochips are being used to improve drug discovery. Nanoscale assays using nanoliter volumes contribute to cost saving. Some nanosubstances such as fullerenes are drug candidates. There are some safety concerns about the in vivo use of nanoparticles that are being investigated. However, future prospects for applications in healthcare of drugs discovered through nanotechnology and their role in the development of personalized medicine appear to be excellent.


Atomic Force Microscopy Gold Nanoparticles Drug Discovery Gelatin Nanoparticles Drug Discov Today 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jain KK. Nanobiotechnology: applications, markets and companies. Jain PharmaBiotech Publications, Basel: Switzerland, 2007:1–695.Google Scholar
  2. 2.
    Jain KK. Nanobiotechnology in Molecular Diagnostics. Norwich, UK: Horizon Scientific Press, 2006:1–185.Google Scholar
  3. 3.
    Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov Today 2005; 10:1435–1442.CrossRefPubMedGoogle Scholar
  4. 4.
    Ozkan M. Quantum dots and other nanoparticles: what can they offer to drug discovery? Drug Discov Today 2004; 9:1065–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Farrer RA, Butterfield FL, Chen VW et al. Highly efficient multiphoton-absorption-induced luminescence from gold nanoparticles. Nano Lett 2005; 5:1139–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Balthasar S, Michaelis K, Dinauer N et al. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005; 26:2723–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Jain KK. Nanoparticles as targeting ligands. Trends Biotechnol 2006 Apr; 24:143–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Won J, Kim M, Yi YW et al. A magnetic nanoprobe technology for detecting molecular interactions in live cells. Science 2005; 309:121–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Hsu HY, Huang YY. RCA combined nanoparticle-based optical detection technique for protein microarray: a novel approach. Biosens Bioelectron 2004; 20, 123–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Ziegler C. Cantilever-based biosensors. Anal Bioanal Chem 2004; 379:946–59.PubMedGoogle Scholar
  11. 11.
    Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65:5317–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Ali SS, Hardt JI, Quick KL et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic Biol Med 2004; 37:1191–202.CrossRefPubMedGoogle Scholar
  13. 13.
    Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005; 5:111–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Jain KK. Personalized Medicine: scientific and commercial aspects. Basel: Jain PharmaBiotech, 2007:1–600.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations